A5081504038- Psoriasis: Treatment and Pathogenesis
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Cancer survivorship and care
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Retinoids in leukemia and cellular processes
- Pharmaceutical studies and practices
- Cytokine Signaling Pathways and Interactions
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Screening and Detection
- Economic and Financial Impacts of Cancer
- Autoimmune and Inflammatory Disorders Research
- Gastric Cancer Management and Outcomes
- Skin Protection and Aging
- Chronic Myeloid Leukemia Treatments
- Global Cancer Incidence and Screening
- Acute Lymphoblastic Leukemia research
- Asthma and respiratory diseases
- Nonmelanoma Skin Cancer Studies
- Antifungal resistance and susceptibility
- Childhood Cancer Survivors' Quality of Life
- Lung Cancer Treatments and Mutations
UCB Pharma (Belgium)
2020-2023
European Organisation for Research and Treatment of Cancer
2003-2005
European Organisation for Research and Treatment of Cancer
2003-2005
Royal Hallamshire Hospital
2003
University of Sheffield
2003
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy safety of bimekizumab as compared with secukinumab, which alone, in patients moderate-to-severe plaque psoriasis have not been extensively examined.
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients moderate-to-severe plaque psoriasis have not been extensively examined.We randomly assigned 1:1:1 ratio to receive subcutaneous at dose 320 mg every 4 weeks for 56 weeks; 16 weeks, then 8 56; or 40 2 24 followed by week 56. primary end points were 90% greater reduction from...
Given the chronic nature of psoriasis and loss response that can be observed with therapies over time, it is important to understand long-term efficacy new treatments.To evaluate maintenance Week 16 responses bimekizumab (BKZ) treatment through Year 3, in patients moderate-to-severe plaque psoriasis.Data were pooled from BKZ-treated 52-week (BE VIVID) 56-week READY BE SURE) phase III studies, their ongoing open-label extension (OLE), BRIGHT. Efficacy outcomes are reported 3 years BKZ an at...
BackgroundBimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab more efficacious than secukinumab over 1 year in the treatment of psoriasis.ObjectiveEvaluate safety and efficacy bimekizumab through 2 years patients with moderate to severe plaque psoriasis.MethodsThe BE RADIANT phase 3b randomized controlled trial consisted 48-week double-blinded period, where received (320 mg every 4 or 8 weeks) (300 weekly Week 4, then weeks), an open-label extension (OLE)....
BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab no unexpected safety findings.To provide and data over 2 years treatment from BRIGHT open-label extension (OLE) in patients moderate-to-severe plaque psoriasis.The 56-week double-blinded phase III randomized controlled trial 1 : to 320 mg every 4 weeks (Q4W), Q4W week 16 then 8 (Q8W), or 40 24 Q4W. After completing SURE, could enter ongoing OLE, possible dosing adjustments based on Psoriasis...
Abstract Background Discontinuation of biologics is common among patients with psoriasis due to treatment failure or adverse events. To achieve improvements in disease management, and clinicians may choose switch biologics. Objectives evaluate the efficacy safety switching bimekizumab from adalimumab, ustekinumab secukinumab. Methods Data are reported for up 80 weeks after switched adalimumab at week 24 BE SURE, 52 VIVID [upon entry into BRIGHT open-label extension (OLE)] secukinumab 48...
The aim of this study was to investigate the consensus skin care advice given by nurses during radiotherapy. Sixty-seven nurses, identified through nine Belgian radiotherapy departments, responded a questionnaire survey consisting 58 items regarding prevention and management erythema, dry desquamation moist desquamation. Consensus for categorized as small if less than 50% gave same answer, moderate between 75% large when more 75%. Overall, 33% showed consensus, 29% 38% consensus. highest...
Bimekizumab treatment resulted in improved clinical outcomes patients with moderate-to-severe plaque psoriasis BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the VIVID Japan patient subpopulation. Globally, were randomized to receive bimekizumab 320 mg every 4 weeks (Q4W), (45/90 weight-based at baseline week 4, then 12 weeks), or placebo (Q4W through 16, Q4W). Efficacy endpoints included 16 Psoriasis Area Severity Index (PASI) 90...
TPS178 Background: Ramucirumab, a human IgG1 monoclonal antibody directed to the ectodomain of VEGFR-2, prevents ligand binding receptor, blocking activation downstream receptor-mediated pathways. Ramucirumab has demonstrated significant improvement in overall survival (OS) and progression-free (PFS) 2 phase III registration studies (REGARD, RAINBOW) patients second-line treatment gastric cancer. This global trial will compare PFS with HER2-negative, metastatic or GEJ adenocarcinoma...
TPS4131 Background: Ramucirumab, a human IgG1 monoclonal antibody directed to the ectodomain of VEGFR-2, prevents ligand binding receptor, blocking activation downstream receptor-mediated pathways. Ramucirumab has demonstrated significant improvement in overall survival (OS) and progression-free (PFS) 2 phase III registration studies (REGARD, RAINBOW) patients second-line treatment gastric cancer. This global trial will compare PFS with HER2-negative, metastatic or GEJ adenocarcinoma...
Abstract not available.
Abstract not available.
Abstract not available.
Abstract not available.
Abstract not available.